HomeCompareCNVVF vs ARCC

CNVVF vs ARCC: Dividend Comparison 2026

CNVVF yields 2.66% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNVVF wins by $233.30M in total portfolio value· pulled ahead in Year 2
10 years
CNVVF
CNVVF
● Live price
2.66%
Share price
$2.63
Annual div
$0.07
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$233.32M
Annual income
$217,615,015.11
Full CNVVF calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — CNVVF vs ARCC

📍 CNVVF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNVVFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNVVF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNVVF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNVVF
Annual income on $10K today (after 15% tax)
$226.24/yr
After 10yr DRIP, annual income (after tax)
$184,972,762.84/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, CNVVF beats the other by $184,972,761.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNVVF + ARCC for your $10,000?

CNVVF: 50%ARCC: 50%
100% ARCC50/50100% CNVVF
Portfolio after 10yr
$116.67M
Annual income
$108,807,508.13/yr
Blended yield
93.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

CNVVF
No analyst data
Altman Z
3.9
Piotroski
7/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNVVF buys
0
ARCC buys
0
No recent congressional trades found for CNVVF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNVVFARCC
Forward yield2.66%10.82%
Annual dividend / share$0.07$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%-50%
Portfolio after 10y$233.32M$24.5K
Annual income after 10y$217,615,015.11$1.16
Total dividends collected$232.13M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: CNVVF vs ARCC ($10,000, DRIP)

YearCNVVF PortfolioCNVVF Income/yrARCC PortfolioARCC Income/yrGap
1$11,232$532.32$11,381$541.15$149.00ARCC
2← crossover$13,136$1,117.60$12,621$284.08+$515.00CNVVF
3$16,499$2,443.06$13,827$145.31+$2.7KCNVVF
4$23,389$5,735.39$15,062$73.43+$8.3KCNVVF
5$40,224$15,197.43$16,364$36.89+$23.9KCNVVF
6$91,892$48,852.40$17,757$18.49+$74.1KCNVVF
7$306,930$208,605.82$19,258$9.25+$287.7KCNVVF
8$1,630,788$1,302,372.58$20,880$4.63+$1.61MCNVVF
9$14,679,140$12,934,196.98$22,636$2.32+$14.66MCNVVF
10$233,321,695$217,615,015.11$24,539$1.16+$233.30MCNVVF

CNVVF vs ARCC: Complete Analysis 2026

CNVVFStock

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Full CNVVF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this CNVVF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNVVF vs SCHDCNVVF vs JEPICNVVF vs OCNVVF vs KOCNVVF vs MAINCNVVF vs HTGCCNVVF vs GBDCCNVVF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.